Basic Information
| LncRNA/CircRNA Name | HOXA11-AS |
| Synonyms | HOXA11-AS, HOXA-AS5, HOXA11-AS1, HOXA11AS, HOXA11S, NCRNA00076 |
| Region | GRCh38_7:27184518-27189293 |
| Ensemble | ENSG00000240990 |
| Refseq | NR_002795 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR etc. |
| Sample | cell lines (A549, H460, 1299, PC9) |
| Expression Pattern | up-regulated |
| Function Description | an up-regulated trend in HOXA11-AS level in NSCLC tissues was found compared to corresponding non-cancerous lung tissues based on qRT-PCR.Additionally, Sun39 et al. investigated the potential mechanism of HOXA11-AS in gastric cancer cells, and they found that HOXA11-AS could play an oncogenic role through the EZH2/HOXA11-AS/LSD1 complex or HOXA11-AS/miR-1297/EZH2 crosstalk. Richards43 et al. NSCLC accounts for approximately 80% of lung cancer, and currently, it still has an unsatisfactory prognosis despite the advances made in its treatments, with an overall 5-year survival rate of less than 16%5,6,7. |
| Pubmed ID | 28717185 |
| Year | 2017 |
| Title | Clinical Significance and Effect of lncRNA HOXA11-AS in NSCLC: A Study Based on Bioinformatics, In Vitro and in Vivo Verification. |
External Links
| Links for HOXA11-AS | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |